Therapeutic potential of Taraxacum officinale against HCV NS5B polymerase: In-vitro and In silico study.

摘要: Discovery of alternative and complementary regimens for HCV infection treatment is a need time from clinical as well economical point views. Low cost bioactive natural compounds production, high biochemical diversity inexistent/milder side effects contribute to new therapies. Aim this study clarify anti-HCV role Taraxacum officinale, habitat plant rich flavonoids. In study, methanol extract T. officinale leaves was initially analyzed its cytotoxic activity in human hepatoma (Huh-7) CHO cell lines. Hepatoma cells were transfected with pCR3.1/Flagtag/HCV NS5B gene cloned vector (genotype 1a) along extract. Considering polymerase potential therapeutic drug target, twelve phytochemicals selected ligands molecular interaction protein using Molecular Operating Environment (MOE) software. Sofosbuvir (Sovaldi: brand name) currently approved drug, used standard current comparative analysis computational docking screening. name indicates plays key viral genome replication. On the basis which targeted determining antiviral 65% inhibition expression documented at nontoxic dose concentration (200μg/ml) Real-time PCR. addition, 57% replication recorded when incubating Huh-7 titer serum infected patients Phytochemicals instance d-glucopyranoside (-31.212 Kcal/mol), Quercetin (-29.222 Luteolin (-26.941 Kcal/mol) some others displayed least binding energies compared (-21.0746 Kcal/mol). Results our strongly revealed that potentially blocked without posing any toxic effect on normal fibroblast body.